New First-Line Option: FDA Approves Acalabrutinib Combo for CLL/SLL

n

A new frontline treatment option is now available for adults diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The U.S. Food and Drug Administration (FDA) has approved a fixed-duration, all-oral combination of Acalabrutinib (Calquence) plus Venetoclax (Venclexta) for previously untreated CLL/SLL.

The approval is based on results from the phase 3 AMPLIFY trial, which demonstrated significant improvements in progression-free survival compared with standard chemoimmunotherapy.

This decision marks an important shift toward time-limited, chemotherapy-free regimens in the first-line treatment of CLL and SLL.

Understanding CLL and SLL

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults in the United States. Small lymphocytic lymphoma (SLL) is closely related to CLL and involves the same cancer cells, but primarily affects lymph nodes rather than the circulating blood.

Historically, frontline treatment options often included chemoimmunotherapy regimens. However, over the past decade, targeted therapies such as BTK inhibitors and BCL-2 inhibitors have transformed the treatment landscape.

What Is Acalabrutinib?

Acalabrutinib is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor. It works by blocking signals that allow malignant B cells to survive and proliferate.

Compared with first-generation BTK inhibitors, Acalabrutinib is more selective, potentially reducing certain off-target side effects.

What Is Venetoclax?

Venetoclax is a BCL-2 inhibitor that promotes apoptosis (programmed cell death) in CLL cells. By targeting a key survival protein, venetoclax helps eliminate cancer cells more directly.

The combination of a BTK inhibitor and a BCL-2 inhibitor targets CLL through complementary mechanisms.

The AMPLIFY Trial: Supporting Data Behind the Approval

The FDA approval was supported by findings from the phase 3 AMPLIFY trial.

Trial Design

The AMPLIFY study compared:

• Acalabrutinib plus venetoclax
  vs
• Standard-of-care chemoimmunotherapy

in adults with previously untreated CLL or SLL.

The primary endpoint was progression-free survival (PFS).

Key Efficacy Results

Topline data showed:

• 3-year PFS rate:
  • 77% with acalabrutinib plus venetoclax
  • 67% with chemoimmunotherapy
• Median PFS:
  • Not reached in the acalabrutinib arm
  • 47.6 months in the comparator arm
• Hazard ratio: 0.65
• P value: .0038

These results demonstrate a statistically significant reduction in the risk of disease progression or death with the acalabrutinib-based regimen.

Importantly, median PFS not being reached indicates that many patients remained progression-free at the time of analysis.

Fixed-Duration, All-Oral Regimen

One of the most notable aspects of this approval is that the regimen is:

• Fully oral
• Chemotherapy-free
• Fixed-duration (14 months)

This is significant because many current frontline regimens involve continuous therapy, which can lead to cumulative toxicity and long-term treatment burden.

Jennifer Brown, MD, PhD, principal investigator of the AMPLIFY trial, emphasized that continuous regimens often carry adverse effects that can become burdensome over time. The approval of this combination provides:

• A time-limited option
• High efficacy
• Good tolerability
• Greater flexibility in treatment planning

Safety Profile

The safety profile of acalabrutinib in the AMPLIFY trial was consistent with prior clinical experience.

Key points:

• No new safety signals were identified
• Adverse events aligned with known effects of BTK inhibitors and venetoclax
• Overall tolerability was considered favorable

Common side effects typically associated with these agents include:

• Headache
• Diarrhea
• Neutropenia
• Fatigue
• Upper respiratory infections

As with other venetoclax-based regimens, tumor lysis syndrome (TLS) risk must be carefully managed at the initiation of treatment.

Why This Approval Matters

This FDA decision represents several important shifts in frontline CLL/SLL management:

1. Move Away From Chemotherapy

Chemoimmunotherapy has long been a standard first-line option. However, targeted therapy combinations are increasingly replacing chemotherapy in many patient populations.

The AMPLIFY data reinforce the role of targeted, chemotherapy-free regimens in newly diagnosed patients.

2. Fixed-Duration Strategy

The 14-month time-limited approach offers:

• Treatment-free intervals after completion
• Reduced cumulative toxicity
• Potential improvement in quality of life

Fixed-duration therapy is particularly appealing for patients who prefer not to remain on indefinite treatment.

3. All-Oral Convenience

An entirely oral regimen removes the need for intravenous chemotherapy, increasing convenience and accessibility for many patients.

Comparison With Other Frontline Options

Frontline CLL/SLL treatment options now include:

• Continuous BTK inhibitor therapy
• Venetoclax-based combinations
• Chemoimmunotherapy (in select patients)

The acalabrutinib plus venetoclax combination adds another highly effective, time-limited option to the treatment algorithm.

The choice among regimens depends on:

• Patient age
• Comorbidities
• Genomic features (e.g., del(17p), TP53 mutation)
• Patient preference
• Risk tolerance

What This Means for Patients

For newly diagnosed adults with CLL or SLL, this approval means:

• More treatment flexibility
• Access to a highly effective first-line regimen
• Option for fixed-duration therapy
• Reduced reliance on chemotherapy

Patients should discuss with their oncologist:

• Whether they are candidates for this regimen
• Potential side effects
• Monitoring requirements
• Long-term expectations

Looking Ahead

The approval of acalabrutinib plus venetoclax reflects the continued evolution of CLL treatment toward:

• Precision targeting
• Chemotherapy-free strategies
• Time-limited therapy models

Ongoing follow-up from AMPLIFY and other trials will help clarify long-term outcomes, including overall survival and durability of response after treatment completion.

Conclusion

The FDA approval of fixed-duration acalabrutinib plus venetoclax as first-line therapy for CLL and SLL represents a meaningful advancement in treatment.

Backed by robust phase 3 data from the AMPLIFY trial, the regimen demonstrated improved progression-free survival compared with chemoimmunotherapy, while maintaining a favorable safety profile.

With its all-oral administration and defined 14-month treatment course, this combination offers patients and physicians a powerful new frontline option that balances efficacy, tolerability, and convenience.

References

1. AstraZeneca. CALQUENCE® plus venetoclax approved in the US as the first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting. News release. February 20, 2026.
2. ClinicalTrials.gov. Study of acalabrutinib (ACP-196) in combination with venetoclax (ABT-199), with and without obinutuzumab (GA101) versus chemoimmunotherapy for previously untreated CLL (AMPLIFY). NCT03836261. Updated December 27, 2024.